Home » Posts tagged with » Reneo Pharmaceuticals
Reneo Pharmaceuticals gets FDA ODD for REN001 in primary mitochondrial myopathies

Reneo Pharmaceuticals gets FDA ODD for REN001 in primary mitochondrial myopathies

Reneo Pharmaceuticals has been granted the orphan drug designation (ODD) for its lead drug candidate REN001 from the US Food and Drug Administration (FDA) for the treatment of primary mitochondrial myopathies (PMM). According to the California-based clinical-stage company, REN001 is a selective PPAR delta agonist, which is being developed for the treatment of genetic myopathies, […]

Reneo Pharmaceuticals launches REN001 clinical trial in McArdle disease

Reneo Pharmaceuticals has initiated a phase 1b clinical trial of REN001 in glycogen storage disease type V (GSD V), also called McArdle disease. The California-based clinical-stage pharma company is currently enrolling participants into the early-stage clinical trial in the UK and Spain. Considered as an inherited disorder, McArdle disease is caused by the body’s inability […]

Continue reading …